Zacks Investment Research upgraded shares of Axcella Health (NASDAQ:AXLA) from a hold rating to a buy rating in a research report released on Tuesday, Zacks.com reports. Zacks Investment Research currently has $2.25 target price on the stock.
According to Zacks, “Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company’s principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical stage. Axcella Health Inc. is based in Cambridge, Massachusetts. “
AXLA has been the topic of several other reports. Chardan Capital boosted their target price on shares of Axcella Health from $10.00 to $12.00 and gave the stock a buy rating in a research report on Tuesday, November 16th. Noble Financial began coverage on shares of Axcella Health in a research note on Tuesday, October 12th. They issued an outperform rating and a $6.00 target price for the company. The Goldman Sachs Group downgraded shares of Axcella Health from a buy rating to a neutral rating and cut their target price for the company from $9.00 to $5.00 in a research note on Wednesday, September 22nd. Finally, Roth Capital reissued a buy rating on shares of Axcella Health in a research note on Thursday, December 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Axcella Health presently has a consensus rating of Buy and an average target price of $8.61.
Axcella Health (NASDAQ:AXLA) last issued its earnings results on Wednesday, November 10th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. Research analysts expect that Axcella Health will post -1.69 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its holdings in shares of Axcella Health by 129.0% during the 2nd quarter. Renaissance Technologies LLC now owns 158,202 shares of the company’s stock worth $634,000 after purchasing an additional 89,115 shares during the period. Geode Capital Management LLC boosted its holdings in Axcella Health by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 140,497 shares of the company’s stock worth $418,000 after acquiring an additional 3,614 shares during the period. Millennium Management LLC boosted its holdings in Axcella Health by 579.6% in the 2nd quarter. Millennium Management LLC now owns 92,688 shares of the company’s stock worth $372,000 after acquiring an additional 79,049 shares during the period. Marshall Wace LLP boosted its holdings in Axcella Health by 31.4% in the 2nd quarter. Marshall Wace LLP now owns 72,422 shares of the company’s stock worth $290,000 after acquiring an additional 17,287 shares during the period. Finally, Ergoteles LLC purchased a new position in Axcella Health in the 2nd quarter worth approximately $257,000. 61.75% of the stock is owned by institutional investors.
Axcella Health Company Profile
Axcella Health, Inc is a biotechnology company. It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy; and AXA1125, for non-alcoholic steatohepatitis.
Featured Article: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.